ClinicalTrials.gg
CompletedNCT02981836Updated Oct 26, 2017

A Blind, Randomized and Controlled Study of Live Attenuated Varicella Vaccines

A Phase 3 interventional study of Investigational live attenuated varicella vaccine and diluent of lyophilized vaccine in Varicella, sponsored by Sinovac (Dalian) Vaccine Technology Co., Ltd.. Completed at 2 sites in China. Open to participants aged 1 Year to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-26.

Sponsored by Sinovac (Dalian) Vaccine Technology Co., Ltd. (part of Sinovac Biotech Co., Ltd) · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Aug 2016, registered Nov 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
5,997
Allocation
Randomized
Ages
1 Year to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing Chickenpox Vaccine in Chickenpox — 5 open to participants now, 7 under way, 4 of them phase 3. Chickenpox Vaccine · Chickenpox.

Enrollment
5th of 36
5,997 · median 404
Started
2016
with 1 other
Phase 3
12 of 36
2 open now
Registered
22nd of 36
by date
Lead sponsor
11 of 36
Sinovac (Dalian) Vaccine Technology Co., Ltd.

Among the 36 studies testing Chickenpox Vaccine in Chickenpox, this one is the 5th largest by enrollment, is one of 2 that started in 2016, is one of 12 in phase 3, and was the 22nd registered.

Chickenpox

180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.

Browse Chickenpox studies →

Open to participants now

5 of the 36 studies testing Chickenpox Vaccine in Chickenpox are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About Chickenpox Vaccine

Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Chickenpox studies recruiting now, 3 (19%) set no upper age limit and 13 (81%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.

This study: 1 Year to 12 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing Chickenpox Vaccine in Chickenpox, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the protective effect, safety and immunogenicity of a live attenuated varicella vaccine in healthy children.

Read the detailed description

This study is a randomized, blind, controlled phase III clinical trial. The purpose of this study is to evaluate the protective effect, safety and immunogenicity of a live attenuated varicella vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. The control is diluent of lyophilized vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. All participants are healthy, and will be randomly assigned into experimental group or control group in the ratio 1:1.

03

Conditions studied

  • Varicella

Browse trials for

Keywords

  • live attenuated varicella vaccine
  • protective effect
  • safety
  • immunogenicity
  • child
04

Who can participate

Ages eligible
1 Year to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteer between 1 - 12 years old;
  • Proven legal identity;
  • Guardian(s) of the volunteer and/or volunteers themselves should be capable of understanding the written consent form, and such form should be signed before the volunteer being included into this study;

Exclusion criteria

Exclusion Criteria:

  • Prior vaccination with varicella vaccine or with history of varicella zoster virus (VZV) infection;
  • Axillaty temperature > 37.0 °C;
  • History of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) to vaccination, such as urticaria, difficulty in breathing, angioneurotic edema, abdominal pain, etc;
  • History of epilepsy, seizures or convulsions, or a family history of mental illness, disease or immunodeficiency;
  • Severe malnutrition, congenital malformation, developmental disorders, or serious chronic diseases;
  • Acute disease or acute stage of chronic disease within 7 days prior to study entry;
  • Receipt of any of the following products:

    1. Any subunit vaccine or inactivated vaccine within 7 days prior to study entry;
    2. Any within 1 month prior to study entry;
    3. Any blood product, , hormone, or other medicine(s) within 30 days prior to study entry;
  • Any significant abnormity of heart, lung, skin, or pharynx;
  • Any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators;
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
5,997 participants (actual)

Study arms

  • Experimental
    Experimental Group

    * Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0; * Intervention: investigational live attenuated varicella vaccine;

    Biological: Investigational live attenuated varicella vaccine

  • Sham comparator
    Control Group

    * Single intramuscular injection of the diluent of lyophilized vaccine (0.5 ml) on Day 0; * Intervention: diluent of lyophilized vaccine;

    Biological: diluent of lyophilized vaccine

Interventions

  • The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.

  • Biologicaldiluent of lyophilized vaccine

    The diluent of lyophilized vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.

06

What researchers measure

Primary outcomes

  1. The incidences of varicella of each group

    The first 30 cases of varicella occurred 30 days after injection will be collected.

    Time frame: ≥30 cases reported 30 days after injection

  2. The protection rate of the vaccine

    The protection rate will be calculated based on the reported cases occurred 30 days after injection.

    Time frame: ≥30 cases reported after 30 days of the injection

Secondary outcomes

  1. The incidences of adverse events (AEs) of each group

    AEs occurred within 30 days after injection will be collected.

    Time frame: 30 days

  2. The incidences of serious adverse events (SAEs) of each group

    SAEs occurred within 6 months after injection will be collected.

    Time frame: 6 months

  3. The seroconversion rate of the immunogenicity group

    Seroconversion rate of the immonogenicity group 30 days after injection will be collected.

    Time frame: 30 days after injection

  4. The geometric mean titer (GMT) of the immunogenicity group

    Geometric mean titer (GMT) of the immonogenicity group will be collected before and 30 days after injection.

    Time frame: 30 days

  5. The geometric mean fold increase (GMI) of the immunogenicity group

    Geometric mean fold increse (GMI) of the immonogenicity group will be calculated based on the geometric mean titer.

    Time frame: 30 days after injection

07

Study locations

2 sites
  • Xiangcheng County Center for Disease Control and Prevention
    Xuchang, Henan 461700, China
  • Biyang County Center for Disease Control and Prevention
    Zhumadian, Henan 463700, China
08

References and documents

Publications

  • Zhang Y, Wang L, Wang Y, Zhang W, Jia N, Xie Z, Huang L, You W, Lu W, Li E, Gao F, Hu Y, Meng F, Xia S. Immunogenicity and Safety of a Booster Dose of Live Attenuated Varicella Vaccine, and Immune Persistence of a Primary Dose for Children Aged 2 to 6 Years. Vaccines (Basel). 2022 Apr 22;10(5):660. doi: 10.3390/vaccines10050660. PubMed 35632416 ↗
  • Hao B, Chen Z, Zeng G, Huang L, Luan C, Xie Z, Chen J, Bao M, Tian X, Xu B, Wang Y, Wu J, Xia S, Yuan L, Huang J. Efficacy, safety and immunogenicity of live attenuated varicella vaccine in healthy children in China: double-blind, randomized, placebo-controlled clinical trial. Clin Microbiol Infect. 2019 Aug;25(8):1026-1031. doi: 10.1016/j.cmi.2018.12.033. Epub 2019 Jan 4. PubMed 30616012 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Jun 2017, 10 months.

Of 35 industry-sponsored phase 3 interventional studies under Chickenpox, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 15. This study's 10 months is below that.

Counting every sponsor, half of 39 studies reached it within 13 months; a quarter within 9 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2016
First posted
Dec 5, 2016
StartActual
Aug 2016
Primary completionActual
Jun 2017
CompletionActual
Sep 2017
Last update
Oct 26, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02981836
Responsible party
Sponsor
First posted
Dec 5, 2016
Start date
Aug 2016
Primary completion
Jun 2017
Completion
Sep 2017
Last update
Oct 26, 2017

Study contacts

Shengli Xia
principal investigator · Henan Provincial Center for Disease Control and Prevention

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chickenpox Vaccine

Start the discussion